136. Colloids Surf B Biointerfaces. 2018 Jun 26;170:596-608. doi:10.1016/j.colsurfb.2018.06.056. [Epub ahead of print]Bacterial cellulose hydrogel loaded with lipid nanoparticles for localized cancertreatment.Cacicedo ML(1), Islan GA(1), León IE(2), Álvarez VA(3), Chourpa I(4),Allard-Vannier E(4), García-Aranda N(5), Díaz-Riascos ZV(6), Fernández Y(5),Schwartz S Jr(7), Abasolo I(8), Castro GR(9).Author information: (1)Nanobiomaterials Lab, CINDEFI, School of Sciences, National University of LaPlata-CONICET (CCT La Plata), 50 & 115 street, CP 1900 AJL, City of La Plata,Buenos Aires, Argentina.(2)Chemical Inorganic Center (CEQUINOR, UNLP, CONICET), School of Sciences,National University of La Plata-CONICET (CCT La Plata), CP 1900 AJL, City of LaPlata, Buenos Aires, Argentina.(3)CoMP (Composite Materials Group), Research Institute of Material Science andTechnology (INTEMA), Engineering School, National University of Mar del Plata,Av. Colón 10890, B7608FDQ, Mar del Plata, Argentina.(4)Université Francois-Rabelais de Tours, EA6295″Nanomedicaments et Nanosondes", 31 Avenue Monge, 37200, Tours, France.(5)Functional Validation & Preclinical Research (FVPR), CIBBIM-Nanomedicine, Valld'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB),08035 Barcelona, Spain; Drug Delivery & Targeting Group, CIBBIM-Nanomedicine,Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona(UAB), 08035 Barcelona, Spain; Networking Research Center on Bioengineering,Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.(6)Functional Validation & Preclinical Research (FVPR), CIBBIM-Nanomedicine, Valld'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB),08035 Barcelona, Spain; Networking Research Center on Bioengineering,Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.(7)Drug Delivery & Targeting Group, CIBBIM-Nanomedicine, Vall d'Hebron Institutde Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona,Spain; Networking Research Center on Bioengineering, Biomaterials andNanomedicine (CIBER-BBN), Barcelona, Spain. Electronic address:simo.schwartz@vhir.org.(8)Functional Validation & Preclinical Research (FVPR), CIBBIM-Nanomedicine, Valld'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB),08035 Barcelona, Spain; Drug Delivery & Targeting Group, CIBBIM-Nanomedicine,Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona(UAB), 08035 Barcelona, Spain; Networking Research Center on Bioengineering,Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain. Electronic address: ibane.abasolo@vhir.org.(9)Nanobiomaterials Lab, CINDEFI, School of Sciences, National University of LaPlata-CONICET (CCT La Plata), 50 & 115 street, CP 1900 AJL, City of La Plata,Buenos Aires, Argentina. Electronic address: grcastro@quimica.unlp.edu.ar.The use of hybrid materials, where a matrix sustains nanoparticles controllingthe release of the chemotherapeutic drug, could be beneficial for the treatmentof primary tumors prior or after surgery. This localized chemotherapy wouldguarantee high drug concentrations at the tumor site while precluding systemicdrug exposure minimizing undesirable side effects. We combined bacterialcellulose hydrogel (BC) and nanostructured lipid carriers (NLCs) includingdoxorubicin (Dox) as a drug model. NLCs loaded with cationic Dox (NLCs-H) orneutral Dox (NLCs-N) were fully characterized and their cell internalization and cytotoxic efficacy were evaluated in vitro against MDA-MB-231 cells. Thereafter, a fixed combination of NLCs-H and NLCs-N loaded into BC (BC-NLCs-NH) was assayed in vivo into an orthotopic breast cancer mouse model. NLCs-H showed lowencapsulation efficiency (48%) and fast release of the drug while NLCs-N showedhigher encapsulation (97%) and sustained drug release. Both NLCs internalized viaendocytic pathway, while allowing a sustained release of the Dox, which in turnrendered IC50 values below of those of free Dox. Taking advantage of thedifferential drug release, a mixture of NLCs-N and NLCs-H was encapsulated intoBC matrix (BC-NLCs-NH) and assayed in vivo, showing a significant reduction oftumor growth, metastasis incidence and local drug toxicities.Copyright © 2018. Published by Elsevier B.V.DOI: 10.1016/j.colsurfb.2018.06.056 PMID: 29975908 